vs
Side-by-side financial comparison of Plymouth Industrial REIT, Inc. (PLYM) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Plymouth Industrial REIT, Inc. is the larger business by last-quarter revenue ($51.2M vs $28.1M, roughly 1.8× ARS Pharmaceuticals, Inc.). Plymouth Industrial REIT, Inc. runs the higher net margin — -106.3% vs -147.1%, a 40.9% gap on every dollar of revenue. On growth, Plymouth Industrial REIT, Inc. posted the faster year-over-year revenue change (-1.4% vs -67.6%).
Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
PLYM vs SPRY — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $51.2M | $28.1M |
| Net Profit | $-54.4M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -102.5% | -147.6% |
| Net Margin | -106.3% | -147.1% |
| Revenue YoY | -1.4% | -67.6% |
| Net Profit YoY | -248.5% | -182.8% |
| EPS (diluted) | $-1.23 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $28.1M | ||
| Q3 25 | $51.2M | $32.5M | ||
| Q2 25 | $47.2M | $15.7M | ||
| Q1 25 | $45.6M | $8.0M | ||
| Q4 24 | $47.6M | $86.6M | ||
| Q3 24 | $51.9M | $2.1M | ||
| Q2 24 | $48.7M | $500.0K | ||
| Q1 24 | $50.2M | $0 |
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $-54.4M | $-51.2M | ||
| Q2 25 | $-6.1M | $-44.9M | ||
| Q1 25 | $5.8M | $-33.9M | ||
| Q4 24 | $147.4M | $49.9M | ||
| Q3 24 | $-15.6M | $-19.1M | ||
| Q2 24 | $1.3M | $-12.5M | ||
| Q1 24 | $6.2M | $-10.3M |
| Q4 25 | — | -147.6% | ||
| Q3 25 | -102.5% | -163.7% | ||
| Q2 25 | -10.3% | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | -29.6% | -1051.6% | ||
| Q2 24 | 2.7% | -3068.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | -147.1% | ||
| Q3 25 | -106.3% | -157.4% | ||
| Q2 25 | -12.9% | -285.6% | ||
| Q1 25 | 12.8% | -425.7% | ||
| Q4 24 | 309.9% | 57.7% | ||
| Q3 24 | -30.1% | -925.0% | ||
| Q2 24 | 2.7% | -2503.2% | ||
| Q1 24 | 12.4% | — |
| Q4 25 | — | $-0.41 | ||
| Q3 25 | $-1.23 | $-0.52 | ||
| Q2 25 | $-0.14 | $-0.46 | ||
| Q1 25 | $0.13 | $-0.35 | ||
| Q4 24 | $3.24 | $0.52 | ||
| Q3 24 | $-0.35 | $-0.20 | ||
| Q2 24 | $0.03 | $-0.13 | ||
| Q1 24 | $0.14 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $470.1M | $114.3M |
| Total Assets | $1.6B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $646.4M | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $114.3M | ||
| Q3 25 | $470.1M | $147.7M | ||
| Q2 25 | $539.6M | $192.3M | ||
| Q1 25 | $571.0M | $229.0M | ||
| Q4 24 | $579.5M | $256.8M | ||
| Q3 24 | $436.5M | $201.0M | ||
| Q2 24 | $475.2M | $215.2M | ||
| Q1 24 | $484.6M | $223.9M |
| Q4 25 | — | $327.7M | ||
| Q3 25 | $1.6B | $372.8M | ||
| Q2 25 | $1.6B | $313.5M | ||
| Q1 25 | $1.4B | $327.3M | ||
| Q4 24 | $1.4B | $351.2M | ||
| Q3 24 | $1.5B | $217.6M | ||
| Q2 24 | $1.4B | $222.0M | ||
| Q1 24 | $1.4B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.12× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-43.5M | ||
| Q3 25 | $20.0M | $-47.0M | ||
| Q2 25 | $23.4M | $-39.6M | ||
| Q1 25 | $15.6M | $-40.7M | ||
| Q4 24 | $96.1M | $42.0M | ||
| Q3 24 | $17.6M | $-14.5M | ||
| Q2 24 | $19.9M | $-7.3M | ||
| Q1 24 | $16.6M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 0.65× | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.12× | — | ||
| Q1 24 | 2.67× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLYM
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
